Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis.
about
Optimal usage of the GnRH antagonists: a review of the literatureRecombinant human follicle-stimulating hormone (r-hFSH) plus recombinant luteinizing hormone versus r-hFSH alone for ovarian stimulation during assisted reproductive technology: systematic review and meta-analysis.Recombinant luteinizing hormone supplementation in women undergoing in vitro fertilization/ intracytoplasmic sperm injection with gonadotropin releasing hormone antagonist protocol: a systematic review and meta-analysis.Gonadotrophins: The future.Comparison of FSH and hMG on ovarian stimulation outcome with a GnRH antagonist protocol in younger and advanced reproductive age women.Individualised controlled ovarian stimulation (iCOS): maximising success rates for assisted reproductive technology patients.Recombinant LH supplementation during IVF cycles with a GnRH-antagonist in estimated poor responders: A cross-matched pilot investigation of the optimal daily dose and timing.Effects of human menopausal gonadotropin on zona pellucida and pregnancy outcomes of ovarian stimulation protocolsImproved pregnancy rates with luteinizing hormone supplementation in patients undergoing ovarian stimulation for IVF.Outcome of in vitro fertilization in patients with proven poor ovarian responsiveness after early vs. mid-follicular LH exposure: a prospective, randomized, controlled studyAddition of low dose hCG to rFSh benefits older women during ovarian stimulation for IVF.Efficacy of low dose hCG on oocyte maturity for ovarian stimulation in poor responder women undergoing intracytoplasmic sperm injection cycle: a randomized controlled trialA large, multicentre, observational, post-marketing surveillance study of the 2:1 formulation of follitropin alfa and lutropin alfa in routine clinical practice for assisted reproductive technology.Luteinizing hormone and follicle stimulating hormone synergy: A review of role in controlled ovarian hyper-stimulation.Controlled ovarian hyperstimulation regimens: a review of the available evidence for clinical practice. Produced on behalf of the BFS Policy and Practice Committee.Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study.Recombinant luteinizing hormone priming in early follicular phase for women undergoing in vitro fertilization: systematic review and meta-analysis.Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders.Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in IVF/ICSI cycles.Comparison between stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF with GnRH antagonist protocol.Effects of propylene glycol or elevated luteinizing hormone during follicle development on ovulation, fertilization, and early embryo development.What are the best predictors for successful GnRH antagonist protocol in in vitro fertilization (IVF) treatment?Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.Recombinant LH administration in subsequent cycle after "unexpected" poor response to recombinant FSH monotherapy.Follicular fluid lipidomics reveals lipid alterations by LH addition during IVF cycles
P2860
Q21245566-2F37D8E1-1089-4BFE-A771-0EA1B2B3040BQ33587150-03371922-898F-4027-81E8-01E1E570CC65Q34631083-495EE708-F8C9-4C66-9B5F-97002D415F6FQ34975528-6AD79E9C-A558-4830-8BEE-F3C8718B6DB5Q34990320-478C31C7-5980-4003-8896-258F2B92592AQ35147438-111E48F5-4F51-4074-ACB9-EAF2098AD271Q35919886-F86BBA57-E9BA-4783-8F70-E587238A882FQ36012119-1C3B14BD-517D-46FF-BB08-3142667D2F7CQ36106422-9A5FAA54-C506-45BF-AAC2-BFEC8F8085DBQ36295608-DF27D9F2-4999-4F98-A4D2-666118C7F1CAQ36299553-D98B3CEA-24F7-4195-B925-8EB460123C04Q36434715-446C5E46-4377-4637-AB80-F183A874BC0EQ37515703-F8756984-18B6-49FA-AC67-4E555ED132CFQ37658028-1E1E856A-A4A8-49DD-BCEF-8221991D85B6Q38109225-5C58492E-1818-491F-ABC0-84FC5C05A8E0Q38120341-59B0FBA8-C56E-447C-91C6-84E69097E3E7Q38193302-73A7C1EB-AE44-4438-BF33-8F43B1E5D855Q38381555-82ED1468-6F4E-4EF7-A846-CDFE669206B2Q38767988-CA3FA027-6410-4544-92A5-51E14A843DC9Q39950550-78A65233-7AF7-4E11-B47C-BD679E29C7B9Q48019745-8EB063EF-9202-432B-BE77-922C409B8289Q48568434-8B496422-1BF4-4426-A261-20455C8E9B03Q48583994-F9E019E2-7DAC-4FF4-8EAB-7550467486F9Q48599302-5ABBA080-6581-4BFF-A982-8E50F22E6CCFQ59203137-60CEC820-59E8-4A84-A8D7-75ECDD68DBE5
P2860
Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Impact of luteinizing hormone ...... les: an age-adjusted analysis.
@en
Impact of luteinizing hormone ...... les: an age-adjusted analysis.
@nl
type
label
Impact of luteinizing hormone ...... les: an age-adjusted analysis.
@en
Impact of luteinizing hormone ...... les: an age-adjusted analysis.
@nl
prefLabel
Impact of luteinizing hormone ...... les: an age-adjusted analysis.
@en
Impact of luteinizing hormone ...... les: an age-adjusted analysis.
@nl
P2093
P50
P1476
Impact of luteinizing hormone ...... les: an age-adjusted analysis.
@en
P2093
Elena Labarta
Ernesto Bosch
Juana Crespo
P304
P356
10.1016/J.FERTNSTERT.2010.10.021
P407
P577
2010-11-10T00:00:00Z